<p>/PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX)（&#34;Volition&#34;）是一家跨国表观遗传学公司，宣布任命医疗与生物实验室有限公司（MBL）为其 Nu.Q® Discover 检测在日本的非独家分销商。</p>
<p><strong>Dr Jasmine Kway</strong>，新加坡 Volition 首席执行官评论道：</p>
<p>&#34;我们很高兴与 MBL 合作，MBL 是日本临床研究工具的领先供应商，特别专注于自身免疫疾病，并拥有良好的业绩记录。</p>
<p>&#34;通过我们的 Nu.Q <em>®</em> Discover 项目，我们现在为全球近 100 个客户提供服务，包括许多顶级制药和诊断公司，加速多个治疗领域的疾病研究和药物开发。这些制药公司中的一些已经进入晚期临床试验，使用我们的检测作为药效学生物标志物。</p>
<p>&#34;我们估计相关伴随诊断的总可达市场略低于 10 亿美元。到 2025 年，我们为 Nu.Q® Discover 带来了可观的收入增长，并预计 2026 年将有类似的增长轨迹。</p>
<p>&#34;我们很高兴通过与 MBL 的协议继续扩展我们的合作网络，并将我们的核小体基础生物标志物的获取扩展到药物开发者和研究人员。</p>
<p>&#34;我们相信，这一合作将引发对使用我们的 Nu.Q®检测进行研究的兴趣和数据，这可能为未来在日本申请诊断状态的监管奠定基础。&#34;</p>
<p>在 2025 年，Volition 宣布了其 Nu.Q® Discover 项目的几个&#34;首次&#34;：</p>
<ol>
<li>Volition 的_高通量合成脓毒症_方法的首次商业销售，该方法实时测量全血中中性粒细胞外陷阱（&#34;NETs&#34;）的激活和抑制，帮助公司开发新的治疗方法以对抗脓毒症和其他与 NETs 相关的疾病。</li>
<li>与一家领先制药公司达成的首次协议，利用 Volition 的 Nu.Q® Discover 生物标志物进行纵向 1/2b 期研究，这是首次在人类临床研究中使用。</li>
<li>与 Hologic Diagenode 达成的联合营销协议，该公司拥有庞大的客户基础和国际影响力，为生物技术和制药公司以及学术和政府组织提供工具。</li>
</ol>
<p>[1] 数据文件：Volition TAM 模型</p>
<p><strong>关于 Nu.Q® Discover</strong></p>
<p>Volition 的 Nu.Q® Discover 项目使药物开发者和科学家能够访问一系列先进的检测工具，用于疾病模型开发、临床前测试和从发现到市场准备的临床研究中的快速表观遗传学分析。</p>
<p>Nu.Q® Discover 基于专有的核小体定量技术。它是药物表观遗传学领域研发专业人员的宝贵研究工具，研究药物反应差异的表观遗传基础。</p>
<p><strong>关于医疗与生物实验室有限公司</strong></p>
<p>MBL 成立于 1969 年，是日本第一家抗体制造商，研究、开发、生产和销售体外诊断（IVD）试剂和基础研究试剂。现在，它的业务不仅扩展到免疫学领域，还扩展到遗传诊断领域。</p>
<p>在 IVD 业务中，他们开发和销售用于自身免疫疾病、癌症、传染病等的 IVD 试剂。特别是在自身抗体诊断领域，他们作为日本领先制造商扩展产品线，为这一领域的许多顽固疾病的医疗提供贡献。在肿瘤学领域，他们通过开发预测药物效果的伴随诊断，为个性化医疗做出贡献。</p>
<p><strong>关于 Volition</strong></p>
<p>Volition 是一家跨国公司，专注于推进表观遗传学科学。Volition 致力于通过早期检测以及疾病和治疗监测，拯救生命并改善人类和动物在重大疾病中的预后。</p>
<p>通过其子公司，Volition 正在开发和商业化简单、易用、成本效益高的血液检测，以帮助检测和监测多种疾病，包括某些癌症和与 NETosis 相关的疾病，如脓毒症。早期检测和监测不仅有潜力延长患者的生命，还能改善他们的生活质量。</p>
<p>Volition 的研发活动主要集中在比利时，在美国设有创新实验室和办公室，并在伦敦设有办公室。</p>
<p>在 Volition 网站地址中找到的内容不被视为本文件的一部分，也不应被视为本文件的一部分。该网站地址仅作为非活动文本引用包含在本文件中。</p>
<p><strong>媒体咨询：</strong> Louise Batchelor，Volition，mediarelations@volition.com +44 (0) 7557 774620</p>
<p><strong>安全港声明</strong></p>
<p>本新闻稿或相关视频或链接中的声明可能是根据《1933 年证券法》第 27A 条及《1934 年证券交易法》第 21E 条的定义的 “前瞻性声明”，涉及可能导致实际结果与前瞻性声明中预期或预测的结果存在重大差异的风险和不确定性。诸如 “预计”、“预期”、“打算”、“计划”、“目标”、“瞄准”、“相信”、“寻求”、“估计”、“优化”、“潜在”、“目标”、“建议”、“可能”、“将”、“应该”、“或许”、“会” 等类似表达识别出前瞻性声明。这些前瞻性声明涉及多个主题，包括 Volition 对收入机会和增长的预期、Volition 的血液基础诊断、预后和疾病监测测试的有效性和可用性、Volition 开发和成功商业化这些测试平台以早期检测癌症和其他疾病的能力，以及作为这些疾病的诊断、预后或疾病监测工具的能力、Volition 对未来出版物的预期、Volition 在与第三方为其产品达成许可和/或分销协议方面的成功，以及 Volition 对这些协议条款的预期。由于众多风险和不确定性，Volition 的实际结果可能与这些前瞻性声明中所指示的结果存在重大差异，包括但不限于测试有效性研究的结果。例如，如果 Volition 未能开发和商业化诊断、预后或疾病监测产品，可能无法执行其运营计划。其他风险和不确定性包括 Volition 未能获得必要的监管许可或批准以分销和营销未来产品；市场未能接受 Volition 开发管道中的产品或 Volition 可能开发的任何其他诊断、预后或疾病监测产品；Volition 未能获得足够的知识产权保护；Volition 将面临激烈的竞争，且由于诊断和疾病监测市场的高度竞争性及其快速的技术变革，Volition 的预期产品可能会变得过时；国内和国际经济的下滑；以及其他风险，包括在 Volition 最近的 10-K 表格年度报告和 10-Q 表格季度报告中识别的风险，以及 Volition 向证券交易委员会提交的其他文件。这些声明基于当前的预期、估计和关于 Volition 业务的预测，部分基于管理层做出的假设。这些声明并不保证未来的表现，并涉及难以预测的风险、不确定性和假设。前瞻性声明是在本发布之日作出的，除法律要求外，Volition 不承担更新其前瞻性声明以反映未来事件或情况的义务。</p>
<p>Nucleosomics™、Capture-PCR™、Capture-Seq™和 Nu.Q®及其各自的标志是 VolitionRx Limited 及其子公司的商标和/或服务标志。本新闻稿或相关视频或链接中提到的所有其他商标、服务标志和商号均为其各自所有者的财产。此外，除非另有说明，所有提及的 “$” 均指美国法定货币。</p>
<p>来源：VolitionRx Limited</p>

4570

VNRX

<p>VolitionRx Limited（纽约证券交易所代码：VNRX）已任命 Medical & Biological Laboratories Co. Ltd（MBL）为其 Nu.Q® Discover 检测在日本的非独家分销商。首席执行官 Dr. Jasmine Kway 对这一合作表示兴奋，旨在增强药物开发者和研究人员对其基于核小体的生物标志物的获取。Volition 预计 Nu.Q® Discover 将实现显著的收入增长，预计可达近 10 亿美元的总可达市场。该合作关系预计将引发对其检测的兴趣，可能导致未来在日本的监管申请</p>

<p>, /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) (&#34;Volition&#34;), a multi-national epigenetics company, announces the appointment of Medical &amp; Biological Laboratories Co. Ltd (MBL) as a non-exclusive distributor of its Nu.Q® Discover assays in Japan.</p>
<div class="lb-trans"><p>/PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX)（&#34;Volition&#34;）是一家跨国表观遗传学公司，宣布任命医疗与生物实验室有限公司（MBL）为其 Nu.Q® Discover 检测在日本的非独家分销商。</p>
</div><p><strong>Dr Jasmine Kway</strong>, Chief Executive Officer, Singapore Volition commented:</p>
<div class="lb-trans"><p><strong>Dr Jasmine Kway</strong>，新加坡 Volition 首席执行官评论道：</p>
</div><p>&#34;We are delighted to be working with MBL, a leading provider of clinical research tools in Japan, with a particular focus and track record in autoimmune diseases.</p>
<div class="lb-trans"><p>&#34;我们很高兴与 MBL 合作，MBL 是日本临床研究工具的领先供应商，特别专注于自身免疫疾病，并拥有良好的业绩记录。</p>
</div><p>&#34;Through our Nu.Q <em>®</em> Discover pillar, we are now serving close to 100 clients worldwide, including many top pharma and diagnostic companies, accelerating disease research and drug development across multiple therapeutic areas. Some of these pharmaceutical companies have progressed to late stage clinical trials using our assays as pharmacodynamic biomarkers.</p>
<div class="lb-trans"><p>&#34;通过我们的 Nu.Q <em>®</em> Discover 项目，我们现在为全球近 100 个客户提供服务，包括许多顶级制药和诊断公司，加速多个治疗领域的疾病研究和药物开发。这些制药公司中的一些已经进入晚期临床试验，使用我们的检测作为药效学生物标志物。</p>
</div><p>&#34;We estimate the Total Accessible Market for relevant companion diagnostics to be a little under $1 billion1. In 2025 we delivered substantial revenue growth for Nu.Q® Discover and anticipate a similar trajectory in 2026.</p>
<div class="lb-trans"><p>&#34;我们估计相关伴随诊断的总可达市场略低于 10 亿美元。到 2025 年，我们为 Nu.Q® Discover 带来了可观的收入增长，并预计 2026 年将有类似的增长轨迹。</p>
</div><p>&#34;We are excited to continue to expand our collaborator network and extend the access to our nucleosome-based biomarkers to drug developers and researchers through this agreement with MBL.</p>
<div class="lb-trans"><p>&#34;我们很高兴通过与 MBL 的协议继续扩展我们的合作网络，并将我们的核小体基础生物标志物的获取扩展到药物开发者和研究人员。</p>
</div><p>&#34;We believe that this collaboration will generate interest and data from using our Nu.Q® assays in research, which may lay the foundation for a possible future regulatory application for diagnostic status in Japan.&#34;</p>
<div class="lb-trans"><p>&#34;我们相信，这一合作将引发对使用我们的 Nu.Q®检测进行研究的兴趣和数据，这可能为未来在日本申请诊断状态的监管奠定基础。&#34;</p>
</div><p>In 2025, Volition announced several &#34;firsts&#34; for its Nu.Q® Discover pillar:</p>
<div class="lb-trans"><p>在 2025 年，Volition 宣布了其 Nu.Q® Discover 项目的几个&#34;首次&#34;：</p>
</div><ol>
<li>The first commercial sale of Volition's <em>High Throughput Synthetic Sepsis</em> method that measures Neutrophil Extracellular Traps (&#34;NETs&#34;) activation and inhibition in whole blood in real time, helping companies develop new therapeutics to combat sepsis and other NETs-related disease.</li>
<li>The first agreement with a leading pharmaceutical company to utilize Volition's Nu.Q® Discover biomarkers in a longitudinal Phase 1/2b study, the first in-human clinical study.</li>
<li>A co-marketing agreement with Hologic Diagenode, which has a large client base and international reach, providing tools to biotech and pharma companies and also to academic and government organizations.</li>
</ol>
<div class="lb-trans"><ol>
<li>Volition 的_高通量合成脓毒症_方法的首次商业销售，该方法实时测量全血中中性粒细胞外陷阱（&#34;NETs&#34;）的激活和抑制，帮助公司开发新的治疗方法以对抗脓毒症和其他与 NETs 相关的疾病。</li>
<li>与一家领先制药公司达成的首次协议，利用 Volition 的 Nu.Q® Discover 生物标志物进行纵向 1/2b 期研究，这是首次在人类临床研究中使用。</li>
<li>与 Hologic Diagenode 达成的联合营销协议，该公司拥有庞大的客户基础和国际影响力，为生物技术和制药公司以及学术和政府组织提供工具。</li>
</ol>
</div><p>[1] Data on File: Volition TAM Model</p>
<div class="lb-trans"><p>[1] 数据文件：Volition TAM 模型</p>
</div><p><strong>About Nu.Q® Discover</strong></p>
<div class="lb-trans"><p><strong>关于 Nu.Q® Discover</strong></p>
</div><p>Volition's Nu.Q® Discover program enables drug developers and scientists access to a range of state-of-the-art assays for rapid epigenetic profiling in disease model development, preclinical testing, and clinical studies from discovery to market ready.</p>
<div class="lb-trans"><p>Volition 的 Nu.Q® Discover 项目使药物开发者和科学家能够访问一系列先进的检测工具，用于疾病模型开发、临床前测试和从发现到市场准备的临床研究中的快速表观遗传学分析。</p>
</div><p>Nu.Q® Discover is built on proprietary nucleosome quantification technology. It is a valuable research tool for R&amp;D professionals working within the field of pharmaco-epigenetics, studying the epigenetic basis for variation in response to drugs.</p>
<div class="lb-trans"><p>Nu.Q® Discover 基于专有的核小体定量技术。它是药物表观遗传学领域研发专业人员的宝贵研究工具，研究药物反应差异的表观遗传基础。</p>
</div><p><strong>About Medical &amp; Biological Laboratories Co., Ltd</strong></p>
<div class="lb-trans"><p><strong>关于医疗与生物实验室有限公司</strong></p>
</div><p>MBL was established in 1969 as the first antibody manufacturer in Japan, and researches, develops, manufactures, and sells reagents of <em>in vitro</em> diagnostics (IVD) and reagents for basic research. It has now expanded its business not only to the immunological field but also to the field of genetic diagnosis.</p>
<div class="lb-trans"><p>MBL 成立于 1969 年，是日本第一家抗体制造商，研究、开发、生产和销售体外诊断（IVD）试剂和基础研究试剂。现在，它的业务不仅扩展到免疫学领域，还扩展到遗传诊断领域。</p>
</div><p>In the IVD business, they develop and sell IVD reagents for autoimmune diseases, cancer, infectious diseases etc. Particularly in the field of autoantibody diagnosis, they are expanding their product lineup as a leading manufacturer in Japan and contributing to medical care in this field where there are many intractable diseases. In the field of oncology, they are contributing to personalized medicine by developing companion diagnostics that predict the effect of drugs.</p>
<div class="lb-trans"><p>在 IVD 业务中，他们开发和销售用于自身免疫疾病、癌症、传染病等的 IVD 试剂。特别是在自身抗体诊断领域，他们作为日本领先制造商扩展产品线，为这一领域的许多顽固疾病的医疗提供贡献。在肿瘤学领域，他们通过开发预测药物效果的伴随诊断，为个性化医疗做出贡献。</p>
</div><p><strong>About Volition</strong></p>
<div class="lb-trans"><p><strong>关于 Volition</strong></p>
</div><p>Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.</p>
<div class="lb-trans"><p>Volition 是一家跨国公司，专注于推进表观遗传学科学。Volition 致力于通过早期检测以及疾病和治疗监测，拯救生命并改善人类和动物在重大疾病中的预后。</p>
</div><p>Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential not only to prolong the life of patients, but also to improve their quality of life.</p>
<div class="lb-trans"><p>通过其子公司，Volition 正在开发和商业化简单、易用、成本效益高的血液检测，以帮助检测和监测多种疾病，包括某些癌症和与 NETosis 相关的疾病，如脓毒症。早期检测和监测不仅有潜力延长患者的生命，还能改善他们的生活质量。</p>
</div><p>Volition's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London.</p>
<div class="lb-trans"><p>Volition 的研发活动主要集中在比利时，在美国设有创新实验室和办公室，并在伦敦设有办公室。</p>
</div><p>The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only.</p>
<div class="lb-trans"><p>在 Volition 网站地址中找到的内容不被视为本文件的一部分，也不应被视为本文件的一部分。该网站地址仅作为非活动文本引用包含在本文件中。</p>
</div><p><strong>Media Enquiries:</strong> Louise Batchelor, Volition, mediarelations@volition.com +44 (0) 7557 774620</p>
<div class="lb-trans"><p><strong>媒体咨询：</strong> Louise Batchelor，Volition，mediarelations@volition.com +44 (0) 7557 774620</p>
</div><p><strong>Safe Harbor Statement</strong></p>
<div class="lb-trans"><p><strong>安全港声明</strong></p>
</div><p>Statements in this press release or associated video or link may be &#34;forward-looking statements&#34; within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as &#34;expects,&#34; &#34;anticipates,&#34; &#34;intends,&#34; &#34;plans,&#34; &#34;aims,&#34; &#34;targets,&#34; &#34;believes,&#34; &#34;seeks,&#34; &#34;estimates,&#34; &#34;optimizing,&#34; &#34;potential,&#34; &#34;goal,&#34; &#34;suggests,&#34; &#34;could,&#34; &#34;would,&#34; &#34;should,&#34; &#34;may,&#34; &#34;will&#34; and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other topics, Volition's expectations related to revenue opportunities and growth, the effectiveness and availability of Volition's blood-based diagnostic, prognostic and disease monitoring tests, Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer and other diseases as well as serving as a diagnostic, prognostic or disease monitoring tools for such diseases, Volition's expectations regarding future publications, Volition's success in securing licensing and/or distribution agreements with third parties for its products, and Volition's expectations regarding the terms of such agreements. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic, prognostic or disease monitoring products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic, prognostic or disease monitoring products Volition might develop; Volition's failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics and disease monitoring market and its rapid technological change; downturns in domestic and foreign economies; and other risks, including those identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.</p>
<div class="lb-trans"><p>本新闻稿或相关视频或链接中的声明可能是根据《1933 年证券法》第 27A 条及《1934 年证券交易法》第 21E 条的定义的 “前瞻性声明”，涉及可能导致实际结果与前瞻性声明中预期或预测的结果存在重大差异的风险和不确定性。诸如 “预计”、“预期”、“打算”、“计划”、“目标”、“瞄准”、“相信”、“寻求”、“估计”、“优化”、“潜在”、“目标”、“建议”、“可能”、“将”、“应该”、“或许”、“会” 等类似表达识别出前瞻性声明。这些前瞻性声明涉及多个主题，包括 Volition 对收入机会和增长的预期、Volition 的血液基础诊断、预后和疾病监测测试的有效性和可用性、Volition 开发和成功商业化这些测试平台以早期检测癌症和其他疾病的能力，以及作为这些疾病的诊断、预后或疾病监测工具的能力、Volition 对未来出版物的预期、Volition 在与第三方为其产品达成许可和/或分销协议方面的成功，以及 Volition 对这些协议条款的预期。由于众多风险和不确定性，Volition 的实际结果可能与这些前瞻性声明中所指示的结果存在重大差异，包括但不限于测试有效性研究的结果。例如，如果 Volition 未能开发和商业化诊断、预后或疾病监测产品，可能无法执行其运营计划。其他风险和不确定性包括 Volition 未能获得必要的监管许可或批准以分销和营销未来产品；市场未能接受 Volition 开发管道中的产品或 Volition 可能开发的任何其他诊断、预后或疾病监测产品；Volition 未能获得足够的知识产权保护；Volition 将面临激烈的竞争，且由于诊断和疾病监测市场的高度竞争性及其快速的技术变革，Volition 的预期产品可能会变得过时；国内和国际经济的下滑；以及其他风险，包括在 Volition 最近的 10-K 表格年度报告和 10-Q 表格季度报告中识别的风险，以及 Volition 向证券交易委员会提交的其他文件。这些声明基于当前的预期、估计和关于 Volition 业务的预测，部分基于管理层做出的假设。这些声明并不保证未来的表现，并涉及难以预测的风险、不确定性和假设。前瞻性声明是在本发布之日作出的，除法律要求外，Volition 不承担更新其前瞻性声明以反映未来事件或情况的义务。</p>
</div><p>Nucleosomics™, Capture-PCR™, Capture-Seq™ and Nu.Q® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release or associated video or link are the property of their respective owners. Additionally, unless otherwise specified, all references to &#34;$&#34; refer to the legal currency of the United States of America.</p>
<div class="lb-trans"><p>Nucleosomics™、Capture-PCR™、Capture-Seq™和 Nu.Q®及其各自的标志是 VolitionRx Limited 及其子公司的商标和/或服务标志。本新闻稿或相关视频或链接中提到的所有其他商标、服务标志和商号均为其各自所有者的财产。此外，除非另有说明，所有提及的 “$” 均指美国法定货币。</p>
</div><p>SOURCE VolitionRx Limited</p>
<div class="lb-trans"><p>来源：VolitionRx Limited</p>
</div>

Volition 宣布任命新的 Nu.Q® Discover 分销商 | Volitionrx 股票新闻